A report of takeover interest from private equity giants EQT AB and KKR & Co. sent shares of Swiss contract drugmaker PolyPeptide Group AG surging more than 15% on Friday. The interest, reported by Bloomberg News citing people with knowledge of the matter, signals a potential wave of consolidation within the pharmaceutical services sector.
"A potential acquisition by a top-tier private equity firm like EQT or KKR would provide PolyPeptide with the capital resources to expand its production capacity and client base," said a markets analyst. "This is a vote of confidence in the long-term growth of the contract drug manufacturing market."
The report, published on April 12, 2026, sparked immediate investor reaction, with PolyPeptide’s stock experiencing its largest single-day gain in over a year. While neither PolyPeptide, EQT, nor KKR have officially commented on the matter, the speculation alone has pushed the company's valuation to a multi-month high. Terms of a potential offer have not been disclosed. The contract drug manufacturing industry, which includes players like Lonza Group AG and Catalent, Inc., has been a focus for private equity due to its stable cash flows and growth potential.
This potential deal highlights the increasing appetite of private equity for specialized healthcare assets. A successful acquisition would likely involve a significant premium to PolyPeptide's recent trading price and could trigger a re-rating for other publicly traded contract drug manufacturers. The next key event for investors will be any official statement from the involved parties, which could come within the next few trading sessions.
This article is for informational purposes only and does not constitute investment advice.
